Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytosorbents Corporation filings document the company's public reporting as a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Recent Form 8-K filings furnish results of operations and financial condition, press release exhibits, Regulation FD disclosures, and other event reports tied to the company's blood purification business.
The filing record also documents regulatory disclosure categories for DrugSorb®-ATR, including FDA and Health Canada communications, De Novo market authorization matters, and related supervisory review or reconsideration processes. Other filings address Nasdaq continued-listing compliance under minimum bid price rules, credit-facility and balance-sheet disclosures reported with earnings releases, and the exhibits that support material corporate updates.
Insider equity awards and holdings reported for Cytosorbents (CTSO). Officer Vincent Capponi was granted 89,100 restricted stock units (RSUs) and a stock option award for 111,100 shares on 08/08/2025. The RSUs vest in equal parts at the first and second anniversaries of the grant and certain RSUs will settle into common stock upon a defined Change in Control. The stock options vest over three years (one-half at year one, one-fourth at year two, one-fourth at year three) and have a stated exercise price of $1 with an expiration in 2035.
Following these reported transactions and the listed previously outstanding awards and shares, the reporting person’s beneficial ownership is shown as 766,268 shares of common stock (direct).
Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corporation (CTSO), was granted equity awards on 08/08/2025. The filing reports an award of 70,000 restricted stock units (RSUs) that vest in equal parts on the first and second anniversaries of the grant, and a grant of 95,000 stock options with an exercise price of $1 that vest one-half on the first anniversary, one-fourth on the second and one-fourth on the third anniversary of the grant.
The disclosure shows these RSUs will settle into common stock upon vesting and notes certain RSUs that vest on a Change In Control (120,000 and 55,000 RSUs). Following the reported transactions, the reporting person beneficially owns 473,025 shares (direct). All information is taken from the Form 4 filing text.
Alan D. Sobel, a director of Cytosorbents Corp (CTSO), reported a substantial disposition and new option grant. The filing shows a disposal of 145,757 shares of Common Stock on 08/08/2025. That disposed amount comprises 69,300 RSUs (grants from 2015–2018 that settle into shares upon a Change in Control) and 76,457 shares owned directly by the reporting person.
Separately, Sobel was granted 22,000 stock options at a $1 exercise price on 08/08/2025; those options vest in four equal quarterly installments over one year and expire on 08/08/2035. The report also notes 2,000 shares held indirectly in the Bernard Sobel Revocable Trust for which he is trustee and beneficiary.
CytoSorbents Corporation (Nasdaq: CTSO) filed a Form 8-K on June 24, 2025 to disclose a material regulatory development. Under Item 8.01 – Other Events, the company reported that it has decided to appeal the U.S. Food & Drug Administration’s (FDA) denial letter related to its De Novo request for DrugSorb-ATR, a blood purification device designed to remove antithrombotic agents during cardiothoracic surgery. The filing furnishes a press release (Exhibit 99.1) as additional detail; however, that release is not included in the body of the 8-K.
The appeal process indicates that management believes there are sufficient grounds to contest the FDA’s decision, but the 8-K offers no timetable, data, or probability of success. No sales, earnings, or forecast information is provided, and no other corporate actions (financing, partnerships, leadership changes) are mentioned. Investors should note that DrugSorb-ATR represents an important U.S. commercial opportunity for CTSO, but the denial—now under appeal—introduces regulatory uncertainty and potential delays to market entry.